You are here
Pfizer Oncology Press Kit
PLEASE NOTE: All assets on this page are intended for use by media professionals.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 18 approved innovative cancer medicines and biosimilars across more than 20 indications, including breast, prostate, kidney, lung and hematology. Pfizer Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for leadership perspective, fact sheets, videos and other media resources. We also encourage you to visit our other online resources for additional information on Pfizer Oncology.
Most recent Articles
18.1 million. That’s the total number of new cancer cases per year expected worldwide in 2018. In Europe specifically, the number of people who will be diagnosed with cancer this year is roughly 4.2 million.
The potential for immunotherapy to transform the lives of people with cancer is vast – and the mountain of data continues to grow. But no matter how effective it may be in fighting certain cancers, it is not – and should not be – the only approach.
In oncology, patients don’t just inspire innovation. They drive it. By its very nature, precision medicine – the cutting edge of oncology – focuses our efforts on people with distinct underlying biological characteristics.
GET TO KNOW PFIZER
PFIZER FACT SHEETS
Headline / Section Title:
ADDITIONAL PFIZER ONCOLOGY RESOURCES